ELDN vs. FIXX, GANX, CKPT, RPHM, BLRX, KRON, CALC, SCYX, IMRX, and KZR
Should you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include Homology Medicines (FIXX), Gain Therapeutics (GANX), Checkpoint Therapeutics (CKPT), Reneo Pharmaceuticals (RPHM), BioLineRx (BLRX), Kronos Bio (KRON), CalciMedica (CALC), SCYNEXIS (SCYX), Immuneering (IMRX), and Kezar Life Sciences (KZR). These companies are all part of the "pharmaceutical preparations" industry.
Eledon Pharmaceuticals (NASDAQ:ELDN) and Homology Medicines (NASDAQ:FIXX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation, community ranking and profitability.
Homology Medicines received 101 more outperform votes than Eledon Pharmaceuticals when rated by MarketBeat users. However, 70.59% of users gave Eledon Pharmaceuticals an outperform vote while only 64.43% of users gave Homology Medicines an outperform vote.
Eledon Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Homology Medicines has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500.
Eledon Pharmaceuticals has higher earnings, but lower revenue than Homology Medicines. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Homology Medicines, indicating that it is currently the more affordable of the two stocks.
Eledon Pharmaceuticals has a net margin of 0.00% compared to Homology Medicines' net margin of -4,779.31%. Eledon Pharmaceuticals' return on equity of -46.15% beat Homology Medicines' return on equity.
Eledon Pharmaceuticals currently has a consensus price target of $10.67, suggesting a potential upside of 420.33%. Homology Medicines has a consensus price target of $0.75, suggesting a potential upside of ∞. Given Homology Medicines' higher possible upside, analysts plainly believe Homology Medicines is more favorable than Eledon Pharmaceuticals.
In the previous week, Eledon Pharmaceuticals' average media sentiment score of 0.00 equaled Homology Medicines'average media sentiment score.
56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 31.3% of Homology Medicines shares are held by institutional investors. 19.4% of Eledon Pharmaceuticals shares are held by company insiders. Comparatively, 16.1% of Homology Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Eledon Pharmaceuticals beats Homology Medicines on 11 of the 15 factors compared between the two stocks.
Get Eledon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eledon Pharmaceuticals Competitors List
Related Companies and Tools
